<h4>Background</h4>In Sub-Saharan Africa, the escalating burden of hypertension converges with persistent malaria endemicity, creating a complex clinical challenge marked by increasing rates of resistance to first-line antihypertensive therapies, particularly angiotensin-converting enzyme inhibitors (ACEIs) and Angiotensin II receptor blockers (ARBs). Here, ACE is linked to malaria.